Andrea Bild Lab

The plan to revolutionize cancer treatment by tracking and responding to evolution of tumor, emergence of resistance, and multimodal AI cell.com/cancer-cell/ab… @Cancer_Cell @ARPA_H

In our latest research, we model how CDK4/6 inhibitor resistant breast cancer cells facilitate growth of sensitive cells, allowing them to evade therapy. Out now in Nature Communications! @dendroicap rdcu.be/dfFL7

I am excited to share that ENDORSE: a prognostic model for endocrine therapy in early and advanced ER+ breast cancers is out now in Molecular Systems Biology!!! @MolSystBiol embopress.org/doi/full/10.15…

ENDORSE: an expression signature-based prognostic model that can predict response to endocrine therapy in ER+ #breastcancer --> bit.ly/3xhIBZ9 @AndreaBildLab @aritromics @cityofhope #biomarker

Most metastatic ER+ breast cancers are treated with hormone therapy until progression. Our latest preprint presents a prognostic model that can identify patients who will likely not benefit from hormone therapy as first-line treatment. medrxiv.org/content/10.110…

We are hiring a Postdoctoral Fellow or Staff Scientist to study tumor heterogeneity and the evolution of treatment refractory states in clinical patient cohorts. Come work with our multidisciplinary team! aa067.referrals.selectminds.com/jobs/postdocto…

Great opportunity for a talented mathematician to work with a dynamic team of clinicians, systems biologists, and data scientists to understand the intricacies of tumor evolution and resistance!

First lab gathering of the year!

Check out our latest research: tepoxalin increases chemotherapy efficacy in breast cancers cells overexpressing MDR1/ABCB1 sciencedirect.com/science/articl…

Looking forward to tuning in to an insightful roundtable on lung cancer tomorrow @DrRaviSalgia!

Our latest work led by Jason Griffiths and Jinfeng Chen exploring convergent mechanisms of resistance to combination cell cycle and endocrine inhibitors in early stage breast cancer is out today in @NatureCancer! rdcu.be/clSy7

Check our latest research on the discovery and evolution of key archetypal phenotypes in single-cell transcriptome of ovarian cancers as they become drug resistant. Led by @aritromics & out now in @NatureComms!!! nature.com/articles/s4146…

Come hear Dr. Bild speak this week in Melbourne! Looking forward to hearing the other speakers as well.

The single-cell eQTLGen Consortium (for immune cells) is 12 men & 2 women. My question is where are the experts? Where are @alexisjbattle, @AnnaCuomo92, @BeEngelhardt, @tuuliel, @jlistgarten, @dana_peer, @meromits, @kerrin_small, @MoniquevdWijst, ... ??? eqtlgen.org/participating.…

Check out the latest publication from the Bild lab! bmccancer.biomedcentral.com/articles/10.11…

GenePattern needs your support! We are preparing a grant proposal for the sustainment of GenePattern server & GenePattern Notebooks. Your email will help underscore their impact when the grant is reviewed. See our blog for more info as to how you can help! tinyurl.com/genepattern-ne…

Let's fix academic posters! Prepping a poster for #SIOP19 and sick of the old "wall-of-text" poster design? Watch this cartoon to see a new, faster approach to designing research posters. Includes templates. #betterposter youtu.be/1RwJbhkCA58

Congrats to Lance and Pierre for presenting their poster at #CSBCPSON2018 yesterday!

Check out our lab's latest review article on tumor heterogeneity! rdcu.be/vzM5

Congrats Shelley and Moom on your recent paper! genomemedicine.biomedcentral.com/articles/10.11…